Literature DB >> 12184361

The global impact of vaccines containing aluminium adjuvants.

C J Clements1, E Griffiths.   

Abstract

Immunization against childhood vaccine-preventable diseases has arguably had the greatest impact on the health of children of any public health intervention. Many of the vaccines used in the Expanded Programme on Immunization (EPI) have contained aluminium-based adjuvants. As such, these adjuvants have played a vital role in enabling the basic vaccines to be used effectively. DTP global supply is fragile and could easily be upset through the loss of even one major vaccine manufacturer. Non-aluminium adjuvants could not readily replace aluminium adjuvants. New generation vaccines will probably need new generation adjuvants. The impact of vaccines with adjuvants is discussed. Having provided decades of reliable, safe service in their relatively simple chemical formulations, adjuvants are likely to be with us, in one form or another, for the indefinite future.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12184361     DOI: 10.1016/s0264-410x(02)00168-8

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  36 in total

1.  Phase I malaria vaccine trial with a long synthetic peptide derived from the merozoite surface protein 3 antigen.

Authors:  Régine Audran; Michel Cachat; Floriana Lurati; Soe Soe; Odile Leroy; Giampietro Corradin; Pierre Druilhe; François Spertini
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

Review 2.  Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide.

Authors:  Daniel Krewski; Robert A Yokel; Evert Nieboer; David Borchelt; Joshua Cohen; Jean Harry; Sam Kacew; Joan Lindsay; Amal M Mahfouz; Virginie Rondeau
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2007       Impact factor: 6.393

3.  Significant systemic and mucosal immune response induced on oral delivery of diphtheria toxoid using nano-bilosomes.

Authors:  Anshuman Shukla; Bhupinder Singh; O P Katare
Journal:  Br J Pharmacol       Date:  2011-09       Impact factor: 8.739

Review 4.  Aluminum exposure and toxicity in neonates: a practical guide to halt aluminum overload in the prenatal and perinatal periods.

Authors:  Daniela Fanni; Rossano Ambu; Clara Gerosa; Sonia Nemolato; Nicoletta Iacovidou; Peter Van Eyken; Vassilios Fanos; Marco Zaffanello; Gavino Faa
Journal:  World J Pediatr       Date:  2014-05-07       Impact factor: 2.764

5.  Enhancement of in vivo and in vitro immune functions by a conformationally biased, response-selective agonist of human C5a: implications for a novel adjuvant in vaccine design.

Authors:  Edward L Morgan; Brandon N Morgan; Elisabeth A Stein; Elizabeth L Vitrs; Marilyn L Thoman; Sam D Sanderson; Joy A Phillips
Journal:  Vaccine       Date:  2009-10-15       Impact factor: 3.641

Review 6.  Biomimetic nanoparticles: preparation, characterization and biomedical applications.

Authors:  Ana Maria Carmona-Ribeiro
Journal:  Int J Nanomedicine       Date:  2010-04-07

Review 7.  Immune mechanisms of protection: can adjuvants rise to the challenge?

Authors:  Amy S McKee; Megan K L MacLeod; John W Kappler; Philippa Marrack
Journal:  BMC Biol       Date:  2010-04-12       Impact factor: 7.431

8.  Gradual reduction of testosterone using a gonadotropin-releasing hormone vaccination delays castration resistance in a prostate cancer model.

Authors:  Jesús A Junco Barranco; Robert P Millar; Franklin Fuentes; Eddy Bover; Eulogio Pimentel; Roberto Basulto; Lesvia Calzada; Rolando Morán; Ayni Rodríguez; Hilda Garay; Osvaldo Reyes; Maria D Castro; Ricardo Bringas; Niurka Arteaga; Henio Toudurí; Mauricio Rabassa; Yairis Fernández; Andrés Serradelo; Eduardo Hernández; Gerardo E Guillén
Journal:  Oncol Lett       Date:  2016-06-07       Impact factor: 2.967

9.  Biomarker-guided screening of Juzen-taiho-to, an oriental herbal formulation for immunostimulation.

Authors:  Anna Takaoka; Maria Iacovidou; Tal H Hasson; Diego Montenegro; Xiangming Li; Moriya Tsuji; Akira Kawamura
Journal:  Planta Med       Date:  2014-02-18       Impact factor: 3.352

10.  Vaccine adjuvants - Current status and prospects on controlled release adjuvancity.

Authors:  S M Sivakumar; Mohammed M Safhi; M Kannadasan; N Sukumaran
Journal:  Saudi Pharm J       Date:  2011-06-25       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.